Maja Kiselinova1, Anna Maria Geretti2, Eva Malatinkova1, Karen Vervisch1, Apostolos Beloukas2, Peter Messiaen3, Pawel Bonczkowski1, Wim Trypsteen1, Steven Callens4, Chris Verhofstede5, Ward De Spiegelaere1, Linos Vandekerckhove6. 1. HIV Translational Research Unit (HTRU), Department of Internal Medicine, Ghent University and Ghent University Hospital, Ghent, Belgium. 2. Department of Clinical Infection, Microbiology and Immunology (CIMI), Institute of Infection and Global Health (IGH), University of Liverpool, Liverpool, UK. 3. Department of Infectious Diseases and Immunity, Jessa Hospital, Hasselt, Belgium. 4. Department of Internal Medicine and Infectious Diseases, Ghent University Hospital, Ghent, Belgium. 5. AIDS Reference Laboratory, Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium. 6. HIV Translational Research Unit (HTRU), Department of Internal Medicine, Ghent University and Ghent University Hospital, Ghent, Belgium Department of Internal Medicine and Infectious Diseases, Ghent University Hospital, Ghent, Belgium linos.vandekerckhove@ugent.be.
Abstract
OBJECTIVES: Whether ART regimens differ in their propensity to allow persistent HIV-1 detection remains unclear. To investigate this, we performed a cross-sectional study to characterize HIV-1 persistence in peripheral blood during suppressive therapy with NRTIs plus a PI or nevirapine. METHODS: Residual plasma HIV-1 RNA was quantified by real-time PCR. Cell-associated proviral total HIV-1 DNA, unspliced and multiply spliced HIV-1 RNA and 2-long terminal repeat (2-LTR) circles were quantified by digital PCR. RESULTS: Comparing PI with nevirapine recipients, residual plasma HIV-1 RNA detection rates were 47/80 (58.8%) versus 37/81 (45.7%), with median (IQR) levels of 4 (3-8) versus 4 (3-7) copies/mL (P = 0.207); detection was less likely with longer duration of suppressive ART (P = 0.020), independently of treatment. HIV-1 DNA was detected in all patients, with median levels of 2.3 (IQR 2.0-2.7) versus 2.5 (IQR 2.1-2.7) log10 copies/10(6) PBMCs, respectively; HIV-1 DNA levels were associated with pre-ART viral load (P = 0.004) and with residual HIV-1 RNA (P = 0.034), unspliced HIV-1 RNA (P = 0.001) and 2-LTR circles (P = 0.005), independently of treatment. CONCLUSIONS: No significant differences were revealed in levels of residual plasma HIV-1 RNA, total HIV-1 DNA or intracellular markers of ongoing virus replication (unspliced and multiply spliced HIV-1 RNA and 2-LTR circles) between treatment groups.
OBJECTIVES: Whether ART regimens differ in their propensity to allow persistent HIV-1 detection remains unclear. To investigate this, we performed a cross-sectional study to characterize HIV-1 persistence in peripheral blood during suppressive therapy with NRTIs plus a PI or nevirapine. METHODS: Residual plasma HIV-1 RNA was quantified by real-time PCR. Cell-associated proviral total HIV-1 DNA, unspliced and multiply spliced HIV-1 RNA and 2-long terminal repeat (2-LTR) circles were quantified by digital PCR. RESULTS: Comparing PI with nevirapine recipients, residual plasma HIV-1 RNA detection rates were 47/80 (58.8%) versus 37/81 (45.7%), with median (IQR) levels of 4 (3-8) versus 4 (3-7) copies/mL (P = 0.207); detection was less likely with longer duration of suppressive ART (P = 0.020), independently of treatment. HIV-1 DNA was detected in all patients, with median levels of 2.3 (IQR 2.0-2.7) versus 2.5 (IQR 2.1-2.7) log10 copies/10(6) PBMCs, respectively; HIV-1 DNA levels were associated with pre-ART viral load (P = 0.004) and with residual HIV-1 RNA (P = 0.034), unspliced HIV-1 RNA (P = 0.001) and 2-LTR circles (P = 0.005), independently of treatment. CONCLUSIONS: No significant differences were revealed in levels of residual plasma HIV-1 RNA, total HIV-1 DNA or intracellular markers of ongoing virus replication (unspliced and multiply spliced HIV-1 RNA and 2-LTR circles) between treatment groups.
Authors: Ann Wiegand; Jonathan Spindler; Feiyu F Hong; Wei Shao; Joshua C Cyktor; Anthony R Cillo; Elias K Halvas; John M Coffin; John W Mellors; Mary F Kearney Journal: Proc Natl Acad Sci U S A Date: 2017-04-17 Impact factor: 11.205
Authors: Stephen Opoku; Samuel Asamoah Sakyi; Nana Kwame Ayisi-Boateng; Anthony Kwame Enimil; Ebenezer Senu; Richard Owusu Ansah; Bismark Dankwah Aning; Diana Atsieno Ojuang; Doreen Nafula Wekesa; Fatima Osman Ahmed; Chidinma B Okeke; Ama Darkoaa Sarfo Journal: AIDS Res Ther Date: 2022-05-25 Impact factor: 2.846
Authors: Maja Kiselinova; Ward De Spiegelaere; Maria Jose Buzon; Eva Malatinkova; Mathias Lichterfeld; Linos Vandekerckhove Journal: PLoS Pathog Date: 2016-03-03 Impact factor: 6.823